B-cell Non-Hodgkins Lymphoma (B-NHL)
Oncology·MeSH: Recurrence
Prevalence
30.0 / 100K
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Compare drugs
Frequently asked questions
How many drugs are in development for B-cell Non-Hodgkins Lymphoma (B-NHL)?
BioSniper tracks 2 drugs in development for B-cell Non-Hodgkins Lymphoma (B-NHL) across 1 company.
How many clinical trials target B-cell Non-Hodgkins Lymphoma (B-NHL)?
There are 1 clinical trial targeting B-cell Non-Hodgkins Lymphoma (B-NHL) tracked by BioSniper.
What is the prevalence of B-cell Non-Hodgkins Lymphoma (B-NHL)?
The estimated prevalence of B-cell Non-Hodgkins Lymphoma (B-NHL) is approximately 30.0 per 100,000 population.
Deep-dive into B-cell Non-Hodgkins Lymphoma (B-NHL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis